TY - JOUR
T1 - Transcatheter mitral valve replacement
T2 - Current evidence and concepts
AU - Demir, Ozan M.
AU - Bolland, Mhairi
AU - Curio, Jonathan
AU - Søndergaard, Lars
AU - Rodés-Cabau, Josep
AU - Redwood, Simon
AU - Prendergast, Bernard
AU - Colombo, Antonio
AU - Chau, Mei
AU - Latib, Azeem
N1 - Funding Information:
Disclosure: JRC receives institutional research grants from and is a consultant for Edwards Lifesciences, Medtronic and Abbott. AL is a consultant for Edwards Lifesciences, Medtronic and Abbott. All other authors have no conflicts of interest to declare. Received: 21 August 2020 Accepted: 4 January 2021 Citation: Interventional Cardiology Review 2021;16:e07. DOI: https://doi.org/10.15420/icr.2020.25 Correspondence: Azeem Latib, Department of Cardiology, Montefiore Medical Center, 111 East 210th St, Bronx, New York 10467–2401, US. E: alatib@gmail.com Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
Publisher Copyright:
© 2021 Radcliffe Group Ltd. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.
AB - Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.
KW - Heart failure
KW - Mitral regurgitation
KW - Percutaneous mitral valve replacement
KW - Transcatheter mitral valve repair
KW - Transcatheter mitral valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85106931299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106931299&partnerID=8YFLogxK
U2 - 10.15420/ICR.2020.25
DO - 10.15420/ICR.2020.25
M3 - Article
AN - SCOPUS:85106931299
SN - 1756-1477
VL - 16
JO - Interventional Cardiology: Reviews, Research, Resources
JF - Interventional Cardiology: Reviews, Research, Resources
ER -